CPRX — Catalyst Pharmaceuticals, Inc.

Catalyst Pharmaceuticals (CPRX) Q3 2025 Earnings Call Summary

1. Key Financial Results and Metrics

• Total Revenue: $148.4 million, up 15.3% year-over-year (Q3 2024: $128.7 million).
• Net Income: GAAP net income of $52.8 million ($0.42 per diluted share), a 20.3% increase from Q3 2024.
• Non-GAAP Net Income: $86.1 million ($0.68 per diluted share), up from $71.1 million ($0.57 per diluted share) in Q3 2024.
• Cash Position: $689.9 million with no debt, reflecting a strong operational cash flow of $163.8 million year-to-date.
• R&D Expenses: $2.7 million, down from $3.3 million in Q3 2024.
• SG&A Expenses: $47.5 million, an increase from $45.9 million in Q3 2024.

2. Strategic Updates and Business Highlights

• FIRDAPSE: Revenue of $92.2 million, a 16.2% increase year-over-year. The company is focusing on expanding its reach in the cancer-associated LEMS market, where 90% of patients are believed to be undiagnosed.
• AGAMREE: Revenue of $32.4 million, a 115.2% increase year-over-year, driven by strong patient retention and adoption across DMD centers of excellence.
• FYCOMPA: Revenue of $23.8 million, down 25.8% year-over-year due to generic competition, but the company raised its full-year guidance to $100-$110 million.
• Share Buyback Program: Authorized to repurchase up to $200 million of common stock between October 2025 and December 2026.
• Business Development: Actively evaluating opportunities for expansion in rare therapeutic areas, leveraging the success of Catalyst Pathways, a patient support program.

3. Forward Guidance and Outlook

• Revenue Guidance: Total revenue for 2025 is now projected between $565 million and $585 million, up from previous estimates.
• FIRDAPSE Guidance: Expected net product revenue between $355 million and $360 million for the year.
• AGAMREE Guidance: Full-year revenue raised to between $105 million and $115 million.
• FYCOMPA Guidance: Revenue guidance increased to $100 million to $110 million, despite anticipated revenue erosion from generics.

4. Bad News, Challenges, or Points of Concern

• FYCOMPA Competition: Revenue decline due to generic entry, with expectations of further erosion as more generics enter the market.
• Patient Loyalty: While there is brand loyalty for FYCOMPA, the company anticipates a decline in revenue due to increased generic competition.
• Market Penetration: The oncology segment for FIRDAPSE is still developing, with significant efforts needed to educate and change care pathways, suggesting a slower adoption rate than initially hoped.

5. Notable Q&A Insights

• FIRDAPSE Oncology Efforts: The company is focusing on educating oncology practices about updated NCCN guidelines, with expectations for significant results in 2026.
• AGAMREE Adoption: Strong engagement from DMD centers, with 43% of patients transitioning from prednisone and 41% from EMFLAZA, indicating broad acceptance.
• Cash Flow Timing: A renegotiated contract led to a one-time cash flow benefit in Q3, with future payments expected to be on a monthly basis rather than bi-monthly.
• Intellectual Property: Confidence in defending patents remains strong, with ongoing litigation against Hetero USA scheduled for March 2026.

Overall, Catalyst Pharmaceuticals reported strong financial results and strategic advancements, particularly in its rare disease therapies, while navigating challenges posed by generic competition and market penetration efforts. The company remains optimistic about its growth trajectory moving into 2026.